Literature DB >> 10891021

Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease.

R K Han1, E D Silverman, A Newman, B W McCrindle.   

Abstract

OBJECTIVE: To determine differences in clinical characteristics, laboratory findings, and cardiac complications between patients with acute Kawasaki disease who received additional treatment for persistent or recurrent fever vs those who did not.
DESIGN: Nonconcurrent case series; medical record review.
SETTING: Tertiary care pediatric hospital. PATIENTS: One hundred eighty-five consecutive patients diagnosed as having acute Kawasaki disease at The Hospital for Sick Children, Toronto, Ontario, from 1995 to 1997. MAIN OUTCOME MEASURE: Prevalence of cardiac complications.
RESULTS: Twenty-one patients (11%) received additional treatment with intravenous gamma globulin (IVGG) with or without intravenous methylprednisolone for persistent fever lasting for more than 48 hours or recurrent fever after initial treatment with IVGG. Patients who received additional treatment did not differ significantly from other patients regarding age, sex, race, or diagnostic criteria. Compared with the patients who did not receive additional therapy, the patients who received additional treatment had shorter median interval from fever onset to initial dose of IVGG (5 vs 6 days; P=.006) and longer total days of fever (9 vs 6 days; P<.001). Initial laboratory investigations did not differ significantly. On initial echocardiography, patients who received additional therapy were significantly more likely to have pericardial effusion (33% vs 15%; P=.04), ventricular dysfunction (14% vs 2%; P= .002), and coronary artery ectasia (76% vs 43%; P=.004) but not aneurysms (10% vs 5%; P= .47). At 12 months after diagnosis, there were no significant differences between the 2 groups regarding the prevalence of coronary artery ectasia or aneurysms.
CONCLUSION: Patients receiving additional treatment for persistent or recurrent fever have similar demographic and clinical characteristics, greater initial cardiac involvement, and similar overall outcomes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891021     DOI: 10.1001/archpedi.154.7.694

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  21 in total

1.  Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.

Authors:  P A Brogan; A Bose; D Burgner; D Shingadia; R Tulloh; C Michie; N Klein; R Booy; M Levin; M J Dillon
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

2.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors:  M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

Review 3.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 4.  Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease.

Authors:  Seyyedeh Saneeymehri; Katherine Baker; Tsz-Yin So
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

5.  Infliximab treatment for pediatric refractory Kawasaki disease.

Authors:  Laura L Blaisdell; Jennifer A Hayman; Adrian M Moran
Journal:  Pediatr Cardiol       Date:  2011-07-20       Impact factor: 1.655

6.  Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy.

Authors:  Masaru Miura; Takuya Tamame; Takashi Naganuma; Shino Chinen; Megumi Matsuoka; Hirotaka Ohki
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

Review 7.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

8.  Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.

Authors:  Hidemasa Sakai; Satoru Iwashima; Shinichiro Sano; Naoe Akiyama; Eiko Nagata; Masashi Harazaki; Tetuya Fukuoka
Journal:  Clin Drug Investig       Date:  2020-12-20       Impact factor: 2.859

9.  Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.

Authors:  Preeti Jaggi; Wei Wang; Igor Dvorchik; Beth Printz; Erika Berry; John P Kovalchin; Karen Texter; Octavio Ramilo; Jane C Burns; Adriana H Tremoulet
Journal:  Pediatr Infect Dis J       Date:  2015-12       Impact factor: 2.129

10.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.